Givlaari
Givlaari ingredients
| Active ingredient | Strength |
|---|---|
| Givosiran Sodium | 189 mg/mL |
What Givlaari is used for
The FDA lists the approved uses on the official label (below). In the EU, givosiran is approved as Givlaari for:
Treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Givlaari
- Generic name
- Givosiran sodium
- Made by
- Alnylam Pharmaceuticals, Inc.
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- Aminolevulinate Synthase 1-directed RNA Interaction, Small Interfering RNA
- FDA approval
- New drug application (NDA) NDA212194
- On the US market since
- 2019
Official information
- Givlaari prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Givosiran sodium)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Givlaari?
Givlaari (Givosiran sodium) is a specialist medicine made by Alnylam Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Givlaari?
Givlaari contains Givosiran Sodium (189 mg/mL).
Is Givlaari approved in Europe?
The same active substance is approved in the EU as Givlaari.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA